Clinical Trials in North Carolina

Showing 15061-15080 of 17,526 trials

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

NCT00583128

The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with non-constipating IBS. The study will test whether or not patients receiving AST-120 experience at least a 50% reduction in the number of days with abdominal pain compared to placebo.

Irritable Bowel Syndrome

Ocera Therapeutics117 participantsStarted Aug 2007

Huntsville, Alabama, United States • Sacramento, California, United States • San Diego, California, United States +14 more locations

COMPLETEDPhase 341 miles

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153

The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.

Pulmonary Disease, Chronic Obstructive

Boehringer Ingelheim1,480 participantsStarted Nov 2006

Birmingham, Alabama, United States • Jasper, Alabama, United States • Mobile, Alabama, United States +177 more locations

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Find Trials by Condition in North Carolina

A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

Enhancing the Prospective Prediction of Psychosis

Female Upper Genital Tract in HIV-infected Women

Magnetic Seizure Therapy (MST) for the Treatment of Major Depression

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Clinical Trial in Females for Female Pattern Hair Loss

Dapagliflozin DPPIV Inhibitor add-on Study

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

AST-120 Used to Treat Mild Hepatic Encephalopathy

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

Effects of School Gardens on Children's Diet, Nutritional Knowledge, Etc.

Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis